Results of the October 2019 Innovation Grants Competition
We are pleased to announce the results of the most recent Innovation Grants competition to support the highest quality creative problem solving in cancer research. Below is a listing of newly awarded Canadian Cancer Society (CCS) Innovation Grants.
Out of a total of 160 eligible grant applications, 24 Canadian Cancer Society Innovation Grants have been approved – a 15% success rate. Funds committed to this competition are made possible by the significant efforts of CCS donors and volunteers across the country and by funding partners. The CIHR Institute of Musculoskeletal Health and Arthritis is supporting 1 Innovation grant. These projects total more than $4.7 million in funding over the full term of these grants.
Abstracts of Innovation Grants
Please note:
- Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
- The start date for these grants is November 1, 2020.
- Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.
Note Carefully:
Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.
Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.
Applicant
Institution
Title
Institution
Title
Award
Attisano, Liliana
University of Toronto
Modelling brain metastasis
University of Toronto
Modelling brain metastasis
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Britton, Robert
Simon Fraser University
Small molecule inhibitors of O GlcNAc transferase: validation of a new anticancer target
Simon Fraser University
Small molecule inhibitors of O GlcNAc transferase: validation of a new anticancer target
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Diallo, Jean Simon
Ottawa Hospital Research Institute
Enhancing oncolytic virus efficacy using effector peptides
Ottawa Hospital Research Institute
Enhancing oncolytic virus efficacy using effector peptides
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Ferbeyre, Gerardo
Université de Montréal
Targeting a novel pyruvate metabolic cycle to restore the senescent tumour suppression mechanism in tumours
Université de Montréal
Targeting a novel pyruvate metabolic cycle to restore the senescent tumour suppression mechanism in tumours
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Ferguson, Sarah
Princess Margaret Cancer Centre UHN
Bariatric surgery for fertility sparing treatment of atypical hyperplasia and grade 1 cancer of the endometrium (B FiERCE): a feasibility study
Princess Margaret Cancer Centre UHN
Bariatric surgery for fertility sparing treatment of atypical hyperplasia and grade 1 cancer of the endometrium (B FiERCE): a feasibility study
2020/2021 : $63,372
2021/2022 : $63,372
2022/2023 : $63,372
2021/2022 : $63,372
2022/2023 : $63,372
Goping, Ing Swie
University of Alberta
Sublethal apoptosis as a driver of breast cancer recurrence
University of Alberta
Sublethal apoptosis as a driver of breast cancer recurrence
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Jaakkimainen, Liisa
Institute for Clinical Evaluative Sciences
Identifying pathways for cancer care from family physicians' electronic medical records
Institute for Clinical Evaluative Sciences
Identifying pathways for cancer care from family physicians' electronic medical records
2020/2021 : $99,746
2021/2022 : $99,945
2021/2022 : $99,945
Kim, Dennis
Princess Margaret Cancer Centre UHN
Clonal stromapoiesis and BM microenvironment in leukemias and HCT
Princess Margaret Cancer Centre UHN
Clonal stromapoiesis and BM microenvironment in leukemias and HCT
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Koromilas, Antonis
Jewish General Hospital
2B or not 2B: that is the question about KRAS function.
Jewish General Hospital
2B or not 2B: that is the question about KRAS function.
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Li, Shawn (Shun Cheng)
Western University
Mechanism of resistance to anti PD 1/L1 immunotherapy and strategies to overcome resistance
Western University
Mechanism of resistance to anti PD 1/L1 immunotherapy and strategies to overcome resistance
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
McCaffrey, Luke
McGill University
Characterizing DCIS heterogeneity and disease progression
McGill University
Characterizing DCIS heterogeneity and disease progression
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Olson, Michael
Ryerson University
MRCK inhibitor optimization for glioblastoma therapy
Ryerson University
MRCK inhibitor optimization for glioblastoma therapy
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Park, Morag
McGill University
Developing therapeutic approaches to treat poor outcome metaplastic breast carcinomas
McGill University
Developing therapeutic approaches to treat poor outcome metaplastic breast carcinomas
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Reilly, Raymond
University of Toronto
Radiation nanomedicine combined with checkpoint immunotherapy for treatment of glioblastoma multiiforme (GBM)
University of Toronto
Radiation nanomedicine combined with checkpoint immunotherapy for treatment of glioblastoma multiiforme (GBM)
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Saleeb, Rola
St. Michael's Hospital
Using nanopore technology to develop rapid, real time, clinical molecular oncology testing
St. Michael's Hospital
Using nanopore technology to develop rapid, real time, clinical molecular oncology testing
2020/2021 : $99,225
2021/2022 : $99,025
2021/2022 : $99,025
Shuhendler, Adam
University of Ottawa
Aldehydes as an imaging biomarker for lung cancer detection and staging by PET
University of Ottawa
Aldehydes as an imaging biomarker for lung cancer detection and staging by PET
2020/2021 : $90,500
2021/2022 : $100,000
2021/2022 : $100,000
Siegel, Peter
McGill University
Characterizing molecular mediators of leptomeningeal metastasis
McGill University
Characterizing molecular mediators of leptomeningeal metastasis
2020/2021 : $63,500
2021/2022 : $66,500
2022/2023 : $70,000
2021/2022 : $66,500
2022/2023 : $70,000
Simunovic, Marko
McMaster University
Pilot study of the rectal cancer checklist and a reminder system to improve pre operative surgeon evaluation of surgical margins among patients with rectal cancer
McMaster University
Pilot study of the rectal cancer checklist and a reminder system to improve pre operative surgeon evaluation of surgical margins among patients with rectal cancer
2020/2021 : $84,467
2021/2022 : $85,918
2021/2022 : $85,918
Stein, Lincoln
Ontario Institute for Cancer Research
Oncolytic virus therapy for U1 mutant cancers
Ontario Institute for Cancer Research
Oncolytic virus therapy for U1 mutant cancers
2020/2021 : $99,979
2021/2022 : $99,979
2021/2022 : $99,979
Watson, Ian
McGill University
Use of oncolytic viruses to overcome immune checkpoint inhibitor resistance in melanoma
McGill University
Use of oncolytic viruses to overcome immune checkpoint inhibitor resistance in melanoma
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Watts, Tania
University of Toronto
Investigating the role of signal 4 on inflammatory monocytes in tissue resident memory T cell formation and control of melanoma during STING agonist therapy
University of Toronto
Investigating the role of signal 4 on inflammatory monocytes in tissue resident memory T cell formation and control of melanoma during STING agonist therapy
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Wright, Frances
Ontario Health
An automated algorithm to identify and characterize skin cancers from population based pathology reports
*co-funded with CIHR-IMHA
Ontario Health
An automated algorithm to identify and characterize skin cancers from population based pathology reports
*co-funded with CIHR-IMHA
2020/2021 : $100,000
2021/2022 : $95,200
2022/2023 : $4,800
2021/2022 : $95,200
2022/2023 : $4,800
Yong, V. Wee
University of Calgary
Unexpected expression of PD1 on brain tumour initiating cells: a novel regulator of glioblastoma growth
University of Calgary
Unexpected expression of PD1 on brain tumour initiating cells: a novel regulator of glioblastoma growth
2020/2021 : $100,000
2021/2022 : $100,000
2021/2022 : $100,000
Zadeh, Gelareh
The Toronto Hospital (Western Division) UHN
Proteogenomics of meningiomas to facilitate molecular classification and identify novel therapeutic options
The Toronto Hospital (Western Division) UHN
Proteogenomics of meningiomas to facilitate molecular classification and identify novel therapeutic options
2020/2021 : $100,000
2021/2022 : $99,570
2021/2022 : $99,570
Last modified on: June 2, 2020